Bausch Health Companies Stock Price, News & Analysis

Bausch Health Companies Inc. is a global diversified pharmaceutical company that develops, manufactures, and markets healthcare products across multiple therapeutic areas. The company operates primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health through its controlling interest in Bausch + Lomb Corporation. With a global workforce of over 7,000 employees, Bausch Health serves patients in approximately 100 countries worldwide.

The company operates through five distinct business segments that address different healthcare markets. The Salix segment focuses on gastroenterology and hepatology products in the United States, treating conditions such as hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, and ulcerative colitis. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products in markets outside the United States. The Solta Medical segment specializes in aesthetic medical devices and non-invasive cosmetic treatments. The Diversified segment encompasses pharmaceutical products in neurology and other therapeutic classes, dermatology products, generic pharmaceuticals, and dentistry products marketed in the United States. The Bausch + Lomb segment consists of the company's global vision care, surgical, consumer, and ophthalmic prescription businesses.

Gastroenterology and Hepatology

Salix Pharmaceuticals, the company's gastroenterology business unit, has operated for over three decades developing and marketing products for gastrointestinal and hepatologic conditions. The flagship product XIFAXAN (rifaximin) represents a significant therapeutic advancement as the first and only FDA-approved medicine for reducing the risk of overt hepatic encephalopathy recurrence in adults. Hepatic encephalopathy is a serious condition affecting liver disease patients, causing brain function impairment due to the liver's inability to remove toxins from the blood. The gastroenterology portfolio addresses various digestive system disorders through both prescription medications and therapeutic solutions designed for specific patient populations with chronic gastrointestinal conditions.

Dermatology and Medical Aesthetics

Through Ortho Dermatologics, Bausch Health has established itself among the largest prescription dermatology companies globally. The dermatology portfolio treats a wide range of skin conditions including acne, psoriasis, atopic dermatitis, and other inflammatory skin disorders. The company markets prescription topical treatments, combination therapies, and specialized dermatological products for both healthcare providers and patients. Solta Medical provides aesthetic solutions that enhance medical device aesthetics practices for physicians. The Thermage technology platform uses monopolar radiofrequency energy to stimulate collagen production and naturally tighten skin through non-invasive procedures. These aesthetic technologies serve the growing market for non-surgical cosmetic treatments, offering alternatives to more invasive procedures for patients seeking facial rejuvenation and body contouring solutions.

Neurology Products

The neurology segment develops and markets pharmaceutical products addressing various neurological conditions affecting the central and peripheral nervous systems. These products treat conditions that impact brain function, nerve health, and neurological symptoms requiring ongoing pharmaceutical management. The neurology portfolio includes both branded prescription medications and specialized formulations designed for chronic neurological disorders that require consistent therapeutic intervention.

Oral Health and Dentistry

OraPharma, the company's oral health business unit, focuses on periodontal disease and other dental health conditions. Periodontal disease affects millions of patients worldwide and requires both professional dental treatments and ongoing maintenance therapies. The dentistry portfolio includes products used by dental professionals in clinical settings as well as prescription medications for managing gum disease and related oral health conditions. These products address the connection between oral health and overall systemic health, as periodontal disease has been linked to various other health conditions.

Eye Health Through Bausch + Lomb

Bausch + Lomb represents a significant component of the company's business, offering a comprehensive portfolio of vision care products. The eye health business encompasses contact lenses, lens care products, ophthalmic pharmaceuticals, intraocular lenses, and ophthalmic surgical equipment. Vision care products serve both consumer and professional markets, providing solutions for vision correction, eye disease management, and surgical interventions. The ophthalmic pharmaceutical portfolio treats conditions such as glaucoma, dry eye, and various inflammatory eye diseases. Surgical products support cataract surgery and other ophthalmic procedures performed by ophthalmologists and eye care professionals worldwide.

Generic and International Pharmaceuticals

The company maintains a portfolio of generic pharmaceutical products that provide affordable alternatives to branded medications across various therapeutic categories. Generic products expand patient access to treatments while generating sustainable revenue streams. The international pharmaceuticals business markets both branded and generic products in markets outside the United States, adapting product portfolios to meet regional healthcare needs and regulatory requirements. This global presence allows the company to serve diverse patient populations with varying healthcare systems and treatment preferences.

Research and Product Development

Bausch Health pursues product development through both internal research programs and strategic acquisitions of companies with promising therapeutic candidates. The company focuses development efforts on therapeutic areas where it maintains existing commercial infrastructure and market expertise. Product development includes both new molecular entities and improved formulations of existing treatments, such as next-generation formulations designed to enhance efficacy, safety, or patient convenience. Strategic acquisitions allow the company to expand therapeutic portfolios while leveraging existing commercial capabilities.

Corporate History and Transformation

The company was formerly known as Valeant Pharmaceuticals International Inc. before changing its name to Bausch Health Companies Inc. in July 2018. The name change reflected a strategic transformation following a period of operational restructuring and renewed focus on core therapeutic areas. The Bausch name honors J.J. Bausch, founder of Bausch & Lomb, which the company acquired to expand its eye health business. The transformation involved debt reduction efforts, portfolio optimization, and refocusing on sustainable growth in key therapeutic segments. Bausch Health maintains its global headquarters in Laval, Quebec, Canada, with U.S. headquarters in Bridgewater, New Jersey.

The company's business model emphasizes developing and acquiring products in therapeutic areas where it can leverage commercial infrastructure and therapeutic expertise. This approach allows Bausch Health to build specialized capabilities in specific disease areas rather than pursuing broad pharmaceutical development across all therapeutic categories. The focused strategy supports efficient resource allocation and enables the company to develop deep relationships with healthcare providers in its core therapeutic areas.